In the future, when people develop resistance to the hormone, they could use the drug to get it back.
The first patient with this gene therapy to undergo this kind of treatment will be a woman in her late 20s, who has lost her ovaries, but who also has a genetic condition that can cause hormone resistance.
In an effort to find out if her condition could be improved with a genetic test, the researchers are now using a technique known as CRISPR to edit the DNA of a woman’s cells and then inserting genes from the DNA into the stem cells of her ovary.
This is an approach that is used to treat ovarian cancer and other types of cell cancers.
If successful, the treatment could potentially improve the quality of life of a female patient who has had ovarian cancer.
“We’re looking at a woman who has ovarian cancer who has an abnormal expression of a particular gene called p53,” says senior author and professor of molecular and cellular biology and of physiology and biophysics at the University of Texas Health Science Center at Houston, Eric Tashkin.
“This gene is expressed in ovarian tissue and it’s known to be affected by ovarian cancer in women.”
He adds that the gene has been implicated in a number of other diseases, including the development of heart disease, diabetes, and Parkinson’s disease.
Tashkins and his colleagues at the Medical College of Georgia have been studying the genetic editing technique called CRISpr/Cas9 to target genes in the ovaries of women with a condition called P53-positive ovarian cancer (PPOC).
The team is now using the CRISPr/Cas 9 technique to edit two gene products in a woman with P53, one that codes for a protein called p-myc, and one that encodes for a DNA-binding protein called T-cell receptor alpha (TCRA).
The researchers hope to find a way to increase the amount of T-cells that are produced in the patient’s ovaries.
The researchers also hope to be able to make more T- cells and increase the quality and number of these cells.
In the past, researchers have used a technique called CpG-protein-coding (CpG)-seq, which measures changes in the expression of the gene product.
These types of gene editing studies usually take place in the lab, where researchers use gene-edited cells to find the changes that occur.
These gene editing techniques can be useful for understanding a gene’s function and can be particularly useful in patients who have genetic diseases that affect the function of other genes, such as cancer.
However, they can also introduce unintended side effects such as cell-death and cancer.
In order to see if the CRispr/CpGs method is able to treat the patient, the scientists have also been looking for potential gene-editing sites on her ovum.
“Our lab has been working on a few different approaches to gene editing, and we found that the best approach is to do a CpGs-seq on a woman that has ovarian cell cancer,” says Tashkov.
“Then we can edit those cells and see what happens.”
The CRisPR/Cas gene editing procedure could help the researchers improve the gene therapy that they have already created in the laboratory.
“By doing gene editing on ovarian tissue, we’re able to generate a drug that is better than current treatments for treating the disease,” Tashkins explains.
In addition to the ovarian cancer patient, Tashenko and his team have been looking at the effect of a genetic screening on the women who would benefit from a gene-based treatment.
One of the most promising potential targets is a gene that codes in the gene for a gene known as the telomerase gene, which helps cells to divide and replicate.
In people with the disease, the telomeres of cells shorten.
This gene may be involved in the development and function of the disease.
The CRISP/Cas system is currently being tested in people with breast cancer, and Tashakov is hopeful that it will be possible to develop a drug to treat women with this type of disease as well.
However it’s important to note that, because the genetic test is currently only being tested on women with ovarian cancer, the results from this study are preliminary.
There are also questions about whether this treatment would be effective in people who are not in their reproductive years, or people with other diseases.
“The most important thing for us is that we can continue to explore the gene-modified tissues in the clinic, and then we can take that knowledge and apply it to people who have other types and other diseases,” Tasheskov says.
“If we can do that, it will give us a better idea of whether we can actually bring down this disease in people.”